Navigation Links
Asoyia Secures Venture Capital Funding
Date:5/1/2008

Soybean seed and oil company will focus on new business development of its

ULTRA low linolenic, trans fat-free products.

IOWA CITY, Iowa, May 1 /PRNewswire/ -- Asoyia has finalized an agreement with two key venture capital firms, securing $4 million to expand marketing, research and development of its ULTRA low linolenic soybean products. Asoyia is the innovator and leader in developing and providing the first and only commercially available soybean oils with the highest level of stability and zero trans fats per serving for the food industry. St. Louis-based Prolog Ventures led the round and was joined by LSP (Life Science Partners) of Boston.

Iowa-based Asoyia produces ULTRA Low Linolenic Soybean Oils (Asoyia-ULL) from the company's 1% ULTRA low linolenic soybeans. The innovative specialty soybeans keep the oil fresh and shelf-stable for two to three times longer than conventional oils thus eliminating the need for hydrogenation which creates trans fat. The FDA began requiring trans fat labeling on all packaged foods in 2006, fueling the food industry's demand for a viable non-hydrogenated oil alternative.

"The new partnership between Asoyia, Prolog and LSP is going to propel us from an established and growing entrepreneurial business into a major marketer of ULTRA low lin oil," said Greg Keeley, Asoyia CEO. "We have an incredibly good product and a demand that's been extremely strong due to the emphasis on health and wellness, the FDA's new labeling legislation, and the banning of trans fat containing oils in some communities like New York City. This will fund our passion for providing a viable, healthy alternative by giving us the working capital we need to bring the company to the next level of success."

Asoyia's ability to meet demand depends on the participation of farmers willing to grow a specialty identity-preserved soybean in lieu of commodity soybeans or corn. The infusion of funding will allow Asoyia's production division to develop an expanding business development team, as well as more delivery points throughout the Midwest. Asoyia will continue to work closely with various genetic suppliers of the 1% ULTRA low lin soybean genetics to develop additional new varieties with improved yield potential and various disease resistance characteristics. Additionally, Asoyia will be better able to capitalize on its strong foothold in the 1% ULTRA low lin soybean seed market by continuing to collaborate with several key seed partners to maximize distribution throughout the entire grain belt region.

"Now we'll be better able to inform farmers, and the agricultural industry in general, that we have a product that is not only unique and profitable, but also good for consumer health and the environment," Keeley explained.

"Asoyia's ULTRA low linolenic soybean products meet a critical need in the marketplace for trans-fat-free alternatives," said Dan Broderick, managing director of Prolog and new board member of Asoyia. "The company's proven products, combined with its seasoned management team, create a strong competitive edge for Asoyia."

Jorg Riesmeier, general partner at LSP and new Asoyia board member said, "LSP is very excited to be part of the Series A round in Asoyia, as the company has already built a track record of success with key soybean oil customers and soybean growers. We look forward to helping Asoyia expand its reach to meet the growing demand for its products."

For more information about Asoyia and Asoyia products, call (877)276-9421 or visit http://www.asoyia.com.

About Asoyia

Formed in 2004 by 25 Iowa farmers, Asoyia grows and processes 1% ULTRA low linolenic soybeans to produce specialty trans fat-free oils. The research, testing and expansion of Asoyia's soybean genetics dates back to the 1960s at Iowa State University, where Dr. Walt Fehr and his team developed the specialty soybean.

About Prolog Ventures

Prolog is a venture capital firm specializing in life science investing. Since its launch in 2001, Prolog has financed more than 20 early-stage companies. The firm is managed by a team of professionals with extensive experience as both investors and entrepreneurs. Prolog focuses on traditional healthcare opportunities as well as emerging areas -- such as nutrition, wellness, plant science, and enabling platforms -- in which it has built one of the largest portfolios in the country. For more information on Prolog, visit http://www.PrologVentures.com.

About LSP

LSP (Life Sciences Partners) is a leading independent venture capital firm, providing private equity financing to early- to mid-stage life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With more than $500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of most experienced specialist life-science investors. Further information on Life Science Partners is available at http://www.lspvc.com.

FOR MORE INFORMATION:

Andrea James

Office: (515)223-1383

Cell: (515) 473-2823


'/>"/>
SOURCE Asoyia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil
2. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
3. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
4. UI licensee Optherion secures $37 million in financing
5. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
6. Piedmont Pharmaceuticals Secures $8.5 Million Investment
7. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
8. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
9. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
10. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
11. InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
(Date:2/13/2016)... ... 2016 , ... Many individuals looking to lead a healthy lifestyle have decreased ... IsoPasta by Isolator Fitness has delved into this niche allowing those giving up their ... IsoPasta has 30 grams of protein and only 7 grams of carbohydrates per ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... PUNE , Maharashtra, February 12, 2016 /PRNewswire/ ... Market research report titled Chronic Inflammation Global ... and a snapshot of the global clinical trials ... the clinical trials by Region, Country (G7 & ... End point status and reviews top companies involved ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 The ... current and future adoption patterns on the usage of ... include the following: - Timeframe of liquid ... types—CTCs, ctDNA, cfDNA and Evs—by organization type - Sample ... sample types: blood, saliva, stool, serum, and so on. ...
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
Breaking Medicine Technology: